Great advances have been made in the treatment of blastomycosis with the advent of stilbamidine and 2-hydroxystilbamidine. The problem of stilbamidine treatment failures is still unanswered. One such case is presented here as it may offer a partial answer to this question.
REVIEW OF LITERATURE
Schoenbach and associates1 reported in 1951 on the favorable response of systemic blastomycosis to stilbamidine. Arthur Curtis2 reported four cases of blastomycosis cured with stilbamidine and diethylstilbesterol in 1952. One treatment success and one failure were reported at the Chicago Dermatologic Society* likewise in 1952. One of the most comprehensive articles, and one of the best, evaluating stilbamidine and its usage, by Dr. D. T. Smith,5 appeared in GP, 1953. Dr. Smith summarized the background and earlier use of stilbamidine in treatment of blastomycoses, presenting detailed information as to dosage, contraindications, and toxic manifestations, together with a brief presenta
KUHN BH. Stilbamidine-Resistant North American BlastomycosisBlastomyces Vaccine Treatment. AMA Arch Derm. 1956;73(6):556–559. doi:10.1001/archderm.1956.01550060026004
Customize your JAMA Network experience by selecting one or more topics from the list below.